Upgrade to SI Premium - Free Trial

Moleculin Biotech (MBRX)

2.40 -0.11 (4.38%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/19/26)

Latest Headlines

Form 8-K Moleculin Biotech, Inc. For: Jun 05 June 5, 2026 8:30 AM - SEC Filing Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML June 5, 2026 8:29 AM - Globe NewsWire Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML June 5, 2026 8:29 AM - StreetInsider Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” Segment June 4, 2026 8:31 AM - StreetInsider Form 8-K Moleculin Biotech, Inc. For: May 29 May 29, 2026 9:26 AM - SEC Filing Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits May 29, 2026 8:21 AM - StreetInsider Form 8-K Moleculin Biotech, Inc. For: May 26 May 26, 2026 8:01 AM - SEC Filing Form 8-K Moleculin Biotech, Inc. For: May 22 May 22, 2026 4:01 PM - SEC Filing Moleculin presents cardiac safety data for Annamycin at 2026 ASCO meeting May 21, 2026 5:02 PM - StreetInsider Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin May 21, 2026 5:02 PM - Globe NewsWire Form 8-K Moleculin Biotech, Inc. For: May 15 May 15, 2026 8:31 AM - SEC Filing Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial May 15, 2026 8:30 AM - Globe NewsWire Form 10-Q Moleculin Biotech, Inc. For: Mar 31 May 14, 2026 4:01 PM - SEC Filing Moleculin nears data unblinding for leukemia drug trial May 13, 2026 8:03 AM - StreetInsider Form 8-K Moleculin Biotech, Inc. For: May 13 May 13, 2026 8:01 AM - SEC Filing Moleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical Benchmarks May 13, 2026 8:00 AM - Globe NewsWire Form 8-K Moleculin Biotech, Inc. For: May 12 May 12, 2026 9:30 AM - SEC Filing Moleculin's Annamycin shows no significant heart toxicity in leukemia study May 12, 2026 9:30 AM - StreetInsider Independent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline Limits May 12, 2026 9:30 AM - Globe NewsWire Independent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline Limits May 12, 2026 9:30 AM - StreetInsider Form 8-K Moleculin Biotech, Inc. For: May 08 May 8, 2026 8:45 AM - SEC Filing Moleculin Biotech receives Hong Kong patent for Annamycin reconstitution method May 8, 2026 8:45 AM - StreetInsider Moleculin Biotech Secures Strategic Additional Patent, Strengthening Global Positioning of Annamycin May 8, 2026 8:45 AM - Globe NewsWire Moleculin's Annamycin shows promise in pancreatic cancer preclinical study April 23, 2026 8:27 AM - StreetInsider Form 8-K Moleculin Biotech, Inc. For: Apr 23 April 23, 2026 8:26 AM - SEC Filing Moleculin’s Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models - Data Presented at AACR 2026 April 23, 2026 8:25 AM - Globe NewsWire Moleculin Announces Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting April 21, 2026 8:36 AM - Globe NewsWire Form 8-K Moleculin Biotech, Inc. For: Apr 15 April 15, 2026 11:41 AM - SEC Filing Form EFFECT Moleculin Biotech, Inc. April 15, 2026 6:23 AM - SEC Filing Form 10-K/A Moleculin Biotech, Inc. For: Dec 31 April 14, 2026 5:27 PM - SEC Filing Form 424B3 Moleculin Biotech, Inc. April 14, 2026 4:57 PM - SEC Filing Moleculin highlights Annamycin's non-cardiotoxic profile in CEO video April 7, 2026 12:52 PM - StreetInsider Moleculin Releases Next CEO Corner Segment Highlighting Annamycin’s Non-Cardiotoxic Profile April 7, 2026 12:52 PM - Globe NewsWire Moleculin highlights Annamycin's non-cardiotoxic profile in CEO segment April 7, 2026 8:42 AM - StreetInsider Moleculin Releases Next CEO Corner Segment Highlighting Annamycin’s Non-Cardiotoxic Profile April 7, 2026 8:41 AM - StreetInsider Moleculin Biotech (MBRX) files for 6.4M share offering by selling stockholders March 27, 2026 4:03 PM - StreetInsider Form S-3 Moleculin Biotech, Inc. March 27, 2026 4:01 PM - SEC Filing Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout March 24, 2026 9:49 AM - Globe NewsWire Moleculin reaches 45-patient milestone in pivotal leukemia trial March 23, 2026 8:33 AM - StreetInsider Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout March 23, 2026 8:32 AM - Globe NewsWire Form 8-K Moleculin Biotech, Inc. For: Mar 23 March 23, 2026 8:30 AM - SEC Filing Form 8-K Moleculin Biotech, Inc. For: Mar 19 March 19, 2026 8:46 AM - SEC Filing Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026 March 19, 2026 8:36 AM - StreetInsider Form 8-K Moleculin Biotech, Inc. For: Mar 19 March 19, 2026 8:35 AM - SEC Filing Form 10-K Moleculin Biotech, Inc. For: Dec 31 March 18, 2026 4:07 PM - SEC Filing Moleculin to Present at 38th Annual ROTH Conference March 17, 2026 9:05 AM - StreetInsider Moleculin releases CEO corner segment on MIRACLE study progress March 11, 2026 9:00 AM - StreetInsider Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study March 11, 2026 9:00 AM - StreetInsider Full Article List